Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting

Abstract

BackgroundAntiemetic effects and safety of granisetron or palonosetron alone and in combination with a corticosteroid against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with Hodgkin lymphoma receiving adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) therapy.MethodsA total of 39 patients were eligible for this study. Before ABVD therapy, granisetron or palonosetron was intravenously administered with or without a corticosteroid (dexamethasone or hydrocortisone) and aprepitant. The proportions of patients with complete control (CC) during the overall (0–120 h after the start of ABVD therapy), acute (0–24 h) and delayed (24–120 h) phases were evaluated. CC was defined as no vomiting and no use of antiemetic rescue medication with only grade 0–1 nausea.ResultsGranisetron and palonosetron were administered in 21 and 18 patients, respectively. The CC rate during the acute, delayed and overall phases was not statistically different between the two groups. The CINV was completely controlled during overall phase in 58.3% of patients receiving granisetron or palonosetron in combination with a corticosteroid, whereas in 11.1% of those without co-treatment of a corticosteroid (P < 0.05). There were significantly higher frequencies of anorexia, leucopenia and neutropenia in the palonosetron group. There is a statistically significant difference in the frequency of febrile neutropenia between presence and absence of a corticosteroid (p = 0.024).ConclusionThese findings suggested that a combination use of a corticosteroid with a 5-HT3 receptor antagonist was preferable for CINV control in patients with Hodgkin lymphoma receiving ABVD therapy, although the careful management of febrile neutropenia is required.Trial registrationThe study approval numbers in the institution; 24–12 and 24–359. Registered April 17, 2012 and June 21, 2012.

Detection of drug safety signal of drug‐induced neutropenia and agranulocytosis in all‐aged patients using electronic medical records

“…The second-generation palonosetron has antiemetic effects superior to those of the first-generation 5-HT3 receptor antagonists ondansetron and dolasetron during the overall, acute, and delayed phases. 12 Significantly higher frequencies of anorexia, leukopenia, and neutropenia were observed in the palonosetron group than the granisetron group in a study of patients with Hodgkin's lymphoma receiving adriamycin bleomycin vinblastine dacarbazine (ABVD) therapy. 13 However, owing to the possible interference of original diseases and chemotherapeutic drugs, further research is required to evaluate the association between palonosetron and neutropenia.…”

The effectiveness of a provincial symptom assessment program in reaching adolescents and young adults with cancer: A population‐based cohort study

“…28,29 Common AYA malignancies such as Hodgkin lymphoma and testicular cancer are also associated with high symptom burdens. 30,31 Given this, it is crucial to know whether universal programs implementing PROMs without specifically targeting AYA are nonetheless successfully reaching this population, both overall and also equitably across subgroups. Previous work had demonstrated that overall in Ontario, younger cancer patients were slightly more likely to undergo ESAS screening than older patients, with a 1% increased chance of being screened for every year decrease in age at the time of diagnosis, but did not specifically examine trends in AYA.…”

Safety and Efficacy of Netupitant/Palonosetron and Dexamethasone in Classical Hodgkin’s Lymphoma Patients with Inadequate Chemotherapy-Induced Nausea and Vomiting Prophylaxis with Palonosetron and Dexamethasone: A Single-Center Real-Life Experience

“…These data are even more important for two reasons; first, even though some data are available for aprepitant in the ABVD setting [15], at our knowledge no data have been published regarding NEPA toxicities in the ABVD setting. Second, our data come from a real-life experience of consecutive patients treated homogeneously at a single center.…”